Article
Oncology
Luis G. Paz-Ares, Tudor-Eliade Ciuleanu, Adam Pluzanski, Jong-Seok Lee, Justin F. Gainor, Gregory A. Otterson, Clarisse Audigier-Valette, Neal Ready, Michael Schenker, Helena Linardou, Reyes Bernabe Caro, Mariano Provencio, Bogdan Zurawski, Ki Hyeong Lee, Sang-We Kim, Claudia Caserta, Suresh S. Ramalingam, David R. Spigel, Julie R. Brahmer, Martin Reck, Kenneth J. O'Byrne, Nicolas Girard, Sanjay Popat, Solange Peters, Arteid Memaj, Faith Nathan, Nivedita Aanur, Hossein Borghaei
Summary: This study assessed the safety and efficacy of first-line nivolumab plus ipilimumab (NIVO+IPI) in a large population of patients with metastatic non-small cell lung cancer (NSCLC). The findings showed that the treatment had relatively lower safety in older patients, but discontinuation did not reduce long-term survival in responders.
JOURNAL OF THORACIC ONCOLOGY
(2023)
Article
Oncology
Lili Mao, Meiyu Fang, Yu Chen, Xiaoting Wei, Jun Cao, Jing Lin, Peng Zhang, Ling Chen, Xiao Cao, Yujun Chen, Jun Guo, Lu Si
Summary: Atezolizumab in combination with bevacizumab shows promising efficacy and manageable safety in patients with advanced mucosal melanoma.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Luis Paz-Ares, Tudor-Eliade Ciuleanu, Manuel Cobo, Michael Schenker, Bogdan Zurawski, Juliana Menezes, Eduardo Richardet, Jaafar Bennouna, Enriqueta Felip, Oscar Juan-Vidal, Aurelia Alexandru, Hiroshi Sakai, Alejo Lingua, Pamela Salman, Pierre-Jean Souquet, Pedro De Marchi, Claudio Martin, Maurice Perol, Arnaud Scherpereel, Shue Lu, Thomas John, David P. Carbone, Stephanie Meadows-Shropshire, Shruti Agrawal, Abderrahim Oukessou, Jinchun Yan, Martin Reck
Summary: The combination of first-line nivolumab plus ipilimumab with a limited course of chemotherapy showed a significant improvement in overall survival for patients with advanced non-small-cell lung cancer, supporting it as a new treatment option for this patient population.
Article
Medicine, General & Internal
Marwan Fakih, Kanwal Pratap Singh Raghav, David Z. Chang, Tim Larson, Allen L. Cohn, Timothy K. Huyck, David Cosgrove, Joseph A. Fiorillo, Rachel Tam, David D'Adamo, Neelesh Sharma, Barbara J. Brennan, Ying A. Wang, Sabine Coppieters, Hong Zebger-Gong, Anke Weispfenning, Henrik Seidel, Bart A. Ploeger, Udo Mueller, Carolina Soares Viana de Oliveira, Andrew Scott Paulson
Summary: This study evaluated the efficacy and safety of regorafenib plus nivolumab in patients with microsatellite stable/mismatch repair-proficient metastatic colorectal cancer. The results showed a certain level of activity in this patient population. However, further studies are needed to identify which patients would benefit most from treatment with regorafenib plus nivolumab.
Article
Oncology
Heinz-Josef Lenz, Eric Van Cutsem, Maria Luisa Limon, Ka Yeung Mark Wong, Alain Hendlisz, Massimo Aglietta, Pilar Garcia-Alfonso, Bart Neyns, Gabriele Luppi, Dana B. Cardin, Tomislav Dragovich, Usman Shah, Sandzhar Abdullaev, Joseph Gricar, Jean-Marie Ledeine, Michael James Overman, Sara Lonardi
Summary: Nivolumab plus low-dose ipilimumab demonstrated robust and durable clinical benefit and was well tolerated as a first-line treatment for MSI-H/dMMR mCRC.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
M. P. Saunders, J. Graham, D. Cunningham, R. Plummer, D. Church, R. Kerr, S. Cook, S. Zheng, N. La Thangue, D. Kerr
Summary: The combination of CXD101 and nivolumab showed good tolerability and efficacy in treating patients with microsatellite stable colorectal carcinoma, achieving control of immune-related diseases and improving survival rates for some patients.
Article
Oncology
T. Andre, S. Lonardi, K. Y. M. Wong, H. -J Lenz, F. Gelsomino, M. Aglietta, E. Van Cutsem, R. McDermott, A. Hill, M. B. Sawyer, A. Hendlisz, B. Neyns, S. Abdullaev, A. Memaj, M. Lei, M. Dixon, S. Kopetz, M. J. Overman, M. A. Morse
Summary: This study confirms the long-term benefit of nivolumab plus low-dose ipilimumab for previously treated patients with MSI-H/dMMR mCRC, with a manageable safety profile.
ANNALS OF ONCOLOGY
(2022)
Article
Oncology
Yuan-Yuan Qu, Hai-Liang Zhang, Hongqian Guo, Hong Luo, Qing Zou, Nianzeng Xing, Shujie Xia, Zhongquan Sun, Xuepei Zhang, Chaohong He, Jinling Cai, Xiao Zhang, Quanren Wang, Ding-Wei Ye
Summary: The combination of camrelizumab and famitinib demonstrated potent and enduring antitumor activity in patients with advanced or metastatic RCC, with a higher objective response rate in treatment-naive patients compared to previously treated patients. The median progression-free survival had not been reached for treatment-naive patients, indicating a promising treatment strategy for this population.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Andrea B. Apolo, Thomas Powles, Bernard Escudier, Mauricio Burotto, Joshua Zhang, Burcin Simsek, Christian Scheffold, Robert J. Motzer, Toni K. Choueiri
Summary: This study analyzed the clinical activity of the nivolumab plus ipilimumab plus cabozantinib triplet combination in previously untreated aRCC patients, showing a certain efficacy but the need for monitoring overlapping toxicities.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Oncology
Assuntina G. Sacco, Ruifeng Chen, Francis P. Worden, Deborah J. L. Wong, Douglas Adkins, Paul Swiecicki, Wanxing Chai-Ho, Peter Oppelt, Debanjali Ghosh, Julie Bykowski, Alfredo Molinolo, Emily Pittman, M. Valeria Estrada, Kathryn Gold, Gregory Daniels, Scott M. Lippman, Amanda Natsuhara, Karen Messer, Ezra E. W. Cohen
Summary: The study aimed to evaluate the anti-tumour activity of PD-1 blockade with EGFR inhibition in recurrent or metastatic head and neck squamous cell carcinoma. Results showed a 45% overall response rate at 6 months for the combination of pembrolizumab and cetuximab.
Article
Oncology
Ticiana Leal, Rupesh Kotecha, Rodryg Ramlau, Li Zhang, Janusz Milanowski, Manuel Cobo, Jaromir Roubec, Lubos Petruzelka, Libor Havel, Sujith Kalmadi, Jeffrey Ward, Zoran Andric, Thierry Berghmans, David E. Gerber, Goetz Kloecker, Rajiv Panikkar, Joachim Aerts, Angelo Delmonte, Miklos Pless, Richard Greil, Christian Rolfo, Wallace Akerley, Michael Eaton, Mussawar Iqbal, Corey Langer
Summary: TTFields therapy has been shown to significantly improve overall survival in patients with metastatic non-small-cell lung cancer, without exacerbating systemic toxicities.
Article
Medicine, General & Internal
Paul Baas, Arnaud Scherpereel, Anna K. Nowak, Nobukazu Fujimoto, Solange Peters, Anne S. Tsao, Aaron S. Mansfield, Sanjay Popat, Thierry Jahan, Scott Antonia, Youssef Oulkhouir, Yolanda Bautista, Robin Cornelissen, Laurent Greillier, Francesco Grossi, Dariusz Kowalski, Jeronimo Rodriguez-Cid, Praveen Aanur, Abderrahim Oukessou, Christine Baudelet, Gerard Zalcman
Summary: Nivolumab plus ipilimumab demonstrated significant improvement in overall survival compared to standard chemotherapy for unresectable malignant pleural mesothelioma. This first-in-class treatment regimen has been approved for previously untreated patients in the USA and showed promising outcomes with manageable adverse events.
Article
Oncology
Robert J. Motzer, Toni K. Choueiri, David F. McDermott, Thomas Powles, Yann-Alexandre Vano, Saurabh Gupta, Jin Yao, Celine Han, Ron Ammar, Simon Papillon-Cavanagh, Shruti S. Saggi, M. Brent McHenry, Petra Ross-Macdonald, Megan Wind-Rotolo
Summary: The study found that biomarkers previously associated with immune checkpoint inhibitor-containing regimens were not predictive for survival in RCC patients treated with nivolumab plus ipilimumab. However, gene expression analysis revealed an association between an inflammatory response and progression-free survival in patients receiving this treatment.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Christopher J. Sweeney, Andrew J. Martin, Martin R. Stockler, Stephen Begbie, Leanna Cheung, Kim N. Chi, Simon Chowdhury, Mark Frydenberg, Lisa G. Horvath, Anthony M. Joshua, Nicola J. Lawrence, Gavin Marx, John McCaffrey, Ray McDermott, Margaret McJannett, Scott A. North, Francis Parnis, Wendy Parulekar, David W. Pook, Martin Neil Reaume, Shahneen K. Sandhu, Alvin Tan, Thean Hsiang Tan, Alastair Thomson, Francisco Vera-Badillo, Scott G. Williams, Diana Winter, Sonia Yip, Alison Y. Zhang, Robert R. Zielinski, Ian Davis
Summary: The ENZAMET trial demonstrated that enzalutamide treatment improved overall survival in patients with metastatic hormone-sensitive prostate cancer. The benefit of enzalutamide was consistent across different prognostic subgroups and in patients who received concurrent docetaxel.
Article
Oncology
Hossein Borghaei, Scott Gettinger, Everett E. Vokes, Laura Q. M. Chow, Marco Angelo Burgio, Javier de Castro Carpeno, Adam Pluzanski, Oscar Arrieta, Osvaldo Aren Frontera, Rita Chiari, Charles Butts, Joanna Wojcik-Tomaszewska, Bruno Coudert, Marina Chiara Garassino, Neal Ready, Enriqueta Felip, Miriam Alonso Garcia, David Waterhouse, Manuel Domine, Fabrice Barlesi, Scott Antonia, Markus Wohlleber, David E. Gerber, Grzegorz Czyzewicz, David R. Spigel, Lucio Crino, Wilfried Enst Erich Eberhardt, Ang Li, Sathiya Marimuthu, Julie Brahmer
Summary: Immunotherapy with nivolumab has shown improved overall survival and safety compared to docetaxel in patients with advanced NSCLC in two phase III trials. Pooled 5-year data demonstrated a significant survival benefit with nivolumab and no new safety concerns.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
